# Evaluate the Efficacy and Safety of Adebrelimab Combined With Chemotherapy With or Without Radiotherapy as Neoadjuvant Treatment for HER2-Negative Locally Advanced Breast Cancer

> **NCT06908668** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Cancer Institute and Hospital, Chinese Academy of Medical Sciences** · enrollment: 170 (estimated)

## Conditions studied

- HER2-Negative Locally Advanced Breast Cancer

## Interventions

- **DRUG:** Neoadjuvant Chemotherapy Combined with Immunotherapy and Radiotherapy
- **DRUG:** Neoadjuvant Chemotherapy Combined with Immunotherapy

## Key facts

- **NCT ID:** NCT06908668
- **Lead sponsor:** Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-03-31
- **Primary completion:** 2028-09-10
- **Final completion:** 2028-09-10
- **Target enrollment:** 170 (ESTIMATED)
- **Last updated:** 2025-04-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06908668

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06908668, "Evaluate the Efficacy and Safety of Adebrelimab Combined With Chemotherapy With or Without Radiotherapy as Neoadjuvant Treatment for HER2-Negative Locally Advanced Breast Cancer". Retrieved via AI Analytics 2026-06-29 from https://api.ai-analytics.org/clinical/NCT06908668. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*